Introduction In a recent development for biologics patents in India, the Delhi High Court has granted interim relief to E.R. Squibb in their infringement suit1 against Zydus Lifesciences. The suit concerns IN 340060, which claims the monoclonal antibody Nivolumab—commercially known as Opdivo®—used in immunotherapy for various cancers. On July 18, 2025, the Court restrained Zydus […]